Literature DB >> 32474578

Monitoring Coronavirus Disease 2019 (COVID-19) Through Trends in Influenza-like Illness, Laboratory-confirmed Influenza, and COVID-19-New York State, Excluding New York City, 1 January 2020-12 April 2020.

Eli S Rosenberg1, Eric W Hall2, Elizabeth M Rosenthal1, Angela M Maxted3, Donna L Gowie3, Elizabeth M Dufort3, Debra S Blog3, Dina Hoefer3, Kirsten St George3, Brad J Hutton3, Howard A Zucker3.   

Abstract

Innovative monitoring approaches are needed to track the coronavirus disease 2019 (COVID-19) epidemic and potentially assess the impact of community mitigation interventions. We present temporal data on influenza-like illness, influenza diagnosis, and COVID-19 cases for all 4 regions of New York State through the first 6 weeks of the outbreak.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; New York; epidemiological monitoring; influenza

Mesh:

Year:  2021        PMID: 32474578      PMCID: PMC7543876          DOI: 10.1093/cid/ciaa684

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


Since 2 March 2020, New York State (NYS) has been experiencing the largest outbreak of coronavirus disease 2019 (COVID-19) in the United States. By the end of March, COVID-19 cases were reported throughout the state; cases outside of New York City (NYC) were concentrated in 1 of 4 New York State Department of Health (NYS DOH) regions (metropolitan region) [1]. In response, state officials implemented a series of community mitigation strategies throughout the month of March that culminated in the “New York on PAUSE” executive order, which closed all nonessential businesses and ordered residents to stay at home [2, 3]. Innovative monitoring approaches are needed to track the epidemic and potentially assess the impact of these interventions. Accurate monitoring of this outbreak is complex and likely influenced by specimen collection supply, provider testing practices, and patient care-seeking behaviors. Since COVID-19 symptoms are similar to those of influenza and other respiratory infections, monitoring influenza-like illness (ILI) alongside diagnostic trends for influenza and COVID-19 could provide a broader understanding of COVID-19, which is often mildly symptomatic and undiagnosed [4, 5]. Given the regional nature of COVID-19 within NYS, a regional monitoring approach may offer early warning and facilitate local planning. Here, we present temporal data on ILI and COVID-19 for all 4 regions of NYS, excluding NYC, as a case study for other settings.

METHODS

Data for this analysis came from 2 sources. First, data on ILI are from the Outpatient Influenza-like Illness Surveillance Network (ILINet) in NYS, which consists of 140 outpatient providers with specialties in emergency medicine, family medicine, internal medicine, pediatrics, employee health, and student health in 49 of 57 NYS counties outside of NYC. Each week, ILINet providers report the aggregate number of all-cause outpatient/emergency department visits and total number of visits with ILI, which is defined as fever of 100°F or greater with cough and/or sore throat in the absence of another known cause. Weekly trends are compared against the regional baseline of 3.2% established by Centers for Disease Control and Prevention (CDC) [6]. Second, data on influenza types A and B and severe acute respiratory syndrome coronavirus 2, the causative agent of COVID-19, are mandatorily reported by laboratories to NYS DOH electronically [7]. Population data are from National Center for Health Statistics bridged-race annual county-level population estimates [8]. NYS DOH operates 4 regional offices (Capital, Central, Western, Metropolitan) that cover all counties outside of NYC [9]. For each week of ILINet data, we aggregated the total number of ILI visits and outpatient visits per region to calculate the regional percent of visits that were for ILI. Additionally, we aggregated the number of new COVID-19 and influenza cases to respectively calculate daily rates (per 100 000 population) and average weekly rates for each disease by region. To align with other disease surveillance data, we present results according to weeks defined by CDC’s Morbidity and Mortality Weekly Report.

RESULTS

In all 4 regions, the average rate of reported laboratory-confirmed influenza cases per 100 000 increased from the beginning of the year until early February before declining through the end of March. From weeks 10 through 14 (1 March–4 April), the average daily influenza case rate decreased by 98.9% in the Central region, 98.7% in the Capital region, 98.4% in the Western region, and 96.9% in the Metropolitan region. After declining for several weeks in February, ILI increased in 3 of the 4 regions starting week 10 and in all 4 regions during week 11 (beginning 8 March) and week 12 (beginning 15 March; Figure 1). Between weeks 10 and 12, the largest increases occurred in the Metropolitan region (3.5% to 9.3%, 2.7-fold change) and the Capital region (4.4% to 7.1%, 1.6-fold change). During week 11 through week 13 (beginning 22 March), all regions exceeded the ILI baseline of 3.2%. Starting with week 13, the percent of visits with ILI decreased in all regions except the Metropolitan region. Between week 13 and week 15 (beginning 5 April), ILI decreased by 60.0% in the Capital region, 65.4% in the Central region, and 45.5% in the Western region. At the end of week 15, ILI was noticeably lower than the baseline of 3.2% in both the Capital (week 15 ILI = 2.9%) and Central (week 15 ILI = 2.3%) regions.
Figure 1.

ILI reported to the Outpatient Influenza-like Illness Surveillance Network, laboratory-confirmed influenza, and laboratory-confirmed COVID-19 reported to surveillance by region in New York State, excluding New York City, 1 January 2020–12 April 12. Capital region: Albany, Clinton, Columbia, Delaware, Essex, Franklin, Fulton, Greene, Hamilton, Montgomery, Otsego, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, Washington counties; Central region: Broome, Cayuga, Chenango, Cortland, Herkimer, Jefferson, Lewis, Madison, Oneida, Onondaga, Oswego, St. Lawrence, Tioga, Tompkins counties; Metropolitan Area region: Dutchess, Nassau, Orange, Putnam, Rockland, Suffolk, Sullivan, Ulster, Westchester counties; Western region: Allegany, Cattaraugus, Chautauqua, Chemung, Erie, Genesee, Livingston, Monroe, Niagara, Ontario, Orleans, Schuyler, Seneca, Steuben, Wayne, Wyoming, Yates counties. COVID-19 cases subject to weekly trends in testing, which typically declines on weekends. Abbreviations: COVID-19 coronavirus 2019; ILI, influenza-like illness.

ILI reported to the Outpatient Influenza-like Illness Surveillance Network, laboratory-confirmed influenza, and laboratory-confirmed COVID-19 reported to surveillance by region in New York State, excluding New York City, 1 January 2020–12 April 12. Capital region: Albany, Clinton, Columbia, Delaware, Essex, Franklin, Fulton, Greene, Hamilton, Montgomery, Otsego, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, Washington counties; Central region: Broome, Cayuga, Chenango, Cortland, Herkimer, Jefferson, Lewis, Madison, Oneida, Onondaga, Oswego, St. Lawrence, Tioga, Tompkins counties; Metropolitan Area region: Dutchess, Nassau, Orange, Putnam, Rockland, Suffolk, Sullivan, Ulster, Westchester counties; Western region: Allegany, Cattaraugus, Chautauqua, Chemung, Erie, Genesee, Livingston, Monroe, Niagara, Ontario, Orleans, Schuyler, Seneca, Steuben, Wayne, Wyoming, Yates counties. COVID-19 cases subject to weekly trends in testing, which typically declines on weekends. Abbreviations: COVID-19 coronavirus 2019; ILI, influenza-like illness. COVID-19 was first confirmed in the Metropolitan region on 2 March before its first diagnosis in the other 3 regions around 1 week later (Capital and Central: 9 March, Western: 11 March). During week 11 and week 12 (8 March–21 March), the slope of daily COVID-19 cases (per 100 000) in each region was 3.6 (Metropolitan), 0.33 (Capital), 0.20 (Central), and 0.17 (Western). During weeks 13–15 (22 March–10 April), the slope of daily COVID-19 cases was lower in all 4 regions (Metropolitan = −0.07, Capital = 0.19, Central = −0.02, Western = 0.14). By the end of week 15, the weekly average rate of new reported COVID-19 cases was 63.3 per 100 000 in the Metropolitan region, 5.5 per 100 000 in the Capital region, 3.1 per 100 000 in the Central region, and 5.7 per 100 000 in the Western region.

Discussion

Until the emergence of COVID-19 in early March, ILI and laboratory-confirmed influenza tracked closely together, with both declining. Thereafter, in the NYS region with the highest rates of confirmed COVID-19 (Metropolitan), ILI increased most sharply. In the other 3 regions, ILI increased ahead of the emergence of COVID-19. This might signal early COVID-19 activity without diagnosis in those regions or increased concern over COVID-19 and care-seeking among people with mild ILI illness. On 16 April, the White House released guidelines for reopening states and regions that are predicated on the monitoring of COVID-19 cases and related symptoms, including ILI activity [10]. This report offers a framework and example for such local monitoring to identify areas in which COVID-19 is emerging or reemerging. Furthermore, observation of ILI, influenza, and COVID-19 case trends throughout the first 6 weeks of the COVID-19 outbreak in NYS can provide insight on the impact of community mitigation policies, beyond cases alone [11]. In the weeks before “New York on PAUSE” (week 13), the average ILI and the daily rate of COVID-19 cases were increasing in all 4 regions. Beginning in week 13, the daily rate of COVID-19 cases stabilized in the Central and Metropolitan regions and ILI decreased in all regions, with Metropolitan ILI decreasing later. The heterogeneity in these indicators across NYS suggests the benefits of a more granular, rather than statewide, approach to monitoring the outbreak and for tailoring the application or suspension of mitigation strategies. While these data provide part of that picture, the inclusion of additional regional data on testing, test positivity, and estimated reproductive number will help further inform strategies [12]. These findings are subject to a few limitations. First, we present the temporal association between policy interventions and ILI activity and COVID-19 rates, but we cannot attribute causality. Second, it is possible that observed ILI, as well as laboratory-confirmed influenza diagnoses, might be lowered by healthcare system efforts to triage mildly ill persons with ILI away from the healthcare setting to alternative COVID-19 testing locations (eg, drive-through or home visit collection) where they would not be captured in the ILINet or tested for influenza. Finally, COVID-19 diagnostic results might be influenced by ongoing changes in COVID-19 testing patterns during the reporting period. Together, these results support use of multiple sources for triangulation in regional monitoring of trends and impact of policies for COVID-19, particularly in locations where the disease is emerging, testing capacity is still being strengthened, and/or influenza is in decline.
  5 in total

1.  Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study.

Authors:  Zaid Haddadin; Jennifer E Schuster; Andrew J Spieker; Herdi Rahman; Anna Blozinski; Laura Stewart; Angela P Campbell; Joana Y Lively; Marian G Michaels; John V Williams; Julie A Boom; Leila C Sahni; Mary Staat; Monica McNeal; Rangaraj Selvarangan; Christopher J Harrison; Geoffrey A Weinberg; Peter G Szilagyi; Janet A Englund; Eileen J Klein; Aaron T Curns; Brian Rha; Gayle E Langley; Aron J Hall; Manish M Patel; Natasha B Halasa
Journal:  Pediatrics       Date:  2021-05-13       Impact factor: 7.124

2.  Systematic Testing for Influenza and Coronavirus Disease 2019 Among Patients With Respiratory Illness.

Authors:  Brendan Flannery; Jennifer K Meece; John V Williams; Emily T Martin; Manjusha Gaglani; Michael L Jackson; H Keipp Talbot
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

3.  SARS-CoV-2/COVID-19 Testing: The Tower of Babel.

Authors:  Chiara Reno; Jacopo Lenzi; Davide Golinelli; Davide Gori; Carlo Signorelli; John Kraemer; Michael A Stoto; Elisa Avitabile; Maria Paola Landini; Tiziana Lazzarotto; Maria Carla Re; Paola Rucci; Gloria Taliani; Davide Trerè; Caterina Vocale; Maria Pia Fantini
Journal:  Acta Biomed       Date:  2020-11-09

4.  When the COVID-19 Pandemic Surges during Influenza Season: Lessons Learnt from the Sentinel Laboratory-Based Surveillance of Influenza-Like Illness in Lombardy during the 2019-2020 Season.

Authors:  Cristina Galli; Laura Pellegrinelli; Laura Bubba; Valeria Primache; Giovanni Anselmi; Serena Delbue; Lucia Signorini; Sandro Binda; Danilo Cereda; Maria Gramegna; Elena Pariani
Journal:  Viruses       Date:  2021-04-16       Impact factor: 5.048

5.  Pediatric emergency department utilization during the COVID-19 pandemic in New York City.

Authors:  William C Sokoloff; William I Krief; Kimberly A Giusto; Tasnima Mohaimin; Cole Murphy-Hockett; Joshua Rocker; Kristy A Williamson
Journal:  Am J Emerg Med       Date:  2021-02-20       Impact factor: 2.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.